AuB
AuB is an intestinal microflora analysis that contributes to the athlete's performance improvement and human health maintenance.
Launch date
Market cap
-
Enterprise valuation
€10—15m (Dealroom.co estimates Sep 2019.)
Tokyo Japan (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$310k | Seed | ||
N/A | JPY55.0m | Series A | |
N/A | JPY8.0m | Series A | |
$2.8m | Series A | ||
$2.3m | Late VC | ||
Total Funding | €5.4m |
Recent News about AuB
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.